New Study Discusses the Superior Safety and Efficacy of Haemonetics' VASCADE MVP® XL for Large-Bore Procedures

New Insights into Haemonetics' VASCADE MVP® XL

In a significant advancement in medical technology, Haemonetics Corporation has published compelling findings regarding its VASCADE MVP® XL vascular closure system. The study compares this system with the existing VASCADE MVP system, particularly in the context of large-bore venous access closure procedures. This groundbreaking research, titled "VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Single-Center Experience on Efficacy and Complications," was recently released in the Journal of Cardiovascular Electrophysiology.

The research involved a cohort of 574 patients who underwent catheter ablation procedures aimed at treating atrial arrhythmia or performing left atrial appendage closure. Notably, certain procedures utilized the VASCADE MVP outside its approved intent, which traditionally includes the use with procedural sheaths measuring between 6F and 12F in inner diameter. The results revealed that the VASCADE MVP XL outperformed its predecessor in critical success metrics, showcasing a consistent safety profile while achieving remarkable hemostasis without complications, which included a striking 0% bleeding ratio.

In March 2026, the VASCADE MVP XL received an expanded approval from the U.S. Food and Drug Administration (FDA) that allows its application in procedures utilizing sheaths of up to 17F in outer diameter. This expanded indication enables its use with state-of-the-art technologies, such as Boston Scientific's FARAPULSE® for pulsed field ablation (PFA) and the WATCHMAN TruSteer® for left atrial appendage closure (LAAC). With these approvals, the VASCADE MVP XL stands out as the only extravascular venous closure system with clinical validation supporting its effectiveness in electrophysiology procedures with larger technological integrations.

The FDA’s endorsement stemmed from evidence collected during the AMBULATE EXPAND trial, a pivotal multi-center examination aimed at evaluating the safety and efficacy of technologies utilizing those larger 17F procedural sheaths. In tandem with this, a significant prospective ultrasound sub-study involving 31 patients, also published recently, provided an imaging-based review of closure sites, illustrating promising early vascular healing outcomes after deployment of the VASCADE MVP XL.

Dr. Jan Hartmann, the Senior Vice President and Chief Medical Officer at Haemonetics, voiced optimism about the implications of this expanded indication. He noted that this approval aligns with the dynamic evolution occurring within the field of electrophysiology, marked by the integration of next-generation PFA and LAAC technologies, along with an increase in the number of simultaneous procedures undertaken.

Dr. Hartmann emphasized, "By facilitating reliable venous closure in large-bore procedures, the VASCADE MVP XL empowers electrophysiology teams to deliver safe and effective care, particularly in outpatient settings like ambulatory surgery centers that are becoming more prevalent." The clinical data surrounding this innovative closure system will play a pivotal role at the upcoming Heart Rhythm Society (HRS) conference, slated for April 2026, where it will be featured in a sponsored session focusing on efficiency in atrial fibrillation ablation.

Haemonetics Corporation, a leader in the global medical technology space, aims to enhance healthcare quality and efficacy through innovative solutions. Their comprehensive suite of products is designed to meet critical medical needs, including advancements in hospital technologies and blood collection systems. For more insights into their products and innovations, you can visit their official website at www.haemonetics.com.

Conclusion

The findings from this study and the subsequent enhancements to the VASCADE MVP XL system not only underscore Haemonetics' commitment to advancing medical technology but also reflect an ongoing dedication to improving patient outcomes in complex healthcare environments. With continued emphasis on innovation, the future looks promising for both the company and its end users in the realm of vascular closure solutions.